Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571697 | 0.92 | EGFR (0.50) | EGFRERBB2TBK1PRKCQGPR119 | |
| SCHEMBL1573307 | 0.91 | EGFR (0.51) | EGFRERBB2TBK1PRKCQGSK3B | |
| SCHEMBL1571689 | 0.87 | EGFR (0.51) | EGFRERBB2TBK1PRKCQGPR119 | |
| SCHEMBL1871547 | 0.83 | EGFR (0.46) | EGFRERBB2TBK1PRKCQGPR119 | |
| SCHEMBL1867720 | 0.80 | EGFR (0.46) | EGFRERBB2TBK1PRKCQGPR119 | |
| SCHEMBL1570915 | 0.78 | TBK1 (0.43) | EGFRERBB2TBK1GPR119JAK2 | |
| SCHEMBL1570681 | 0.76 | GRM5 (0.40) | EGFRTBK1GPR119JAK2JAK3 | |
| SCHEMBL1872243 | 0.76 | GPR119 (0.44) | EGFRERBB2GPR119GSK3BDYRK1A | |
| SCHEMBL12671569 | 0.76 | JAK2 (0.38) | EGFRERBB2TBK1JAK2JAK3 | |
| SCHEMBL13362934 | 0.75 | JAK2 (0.42) | EGFRTBK1GPR119JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | EGFR 1733/4885ERBB2 1242/4885TBK1 493/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | EGFR 1053/4885ERBB2 1020/4885TBK1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.